TG Therapeutics Lifts 2026 Revenue Guidance to ~$1B as BRIUMVI Grows 52%
TGTX has more than doubled off its 52-week low of $26.76.
Summary
TG Therapeutics posted Q3 2026 revenue of $259.9 million and net income of $55.5 million, then raised full-year revenue guidance to approximately $1 billion. It also repurchased about $100 million of stock in the quarter.
Key Events · Earnings and Guidance · TGTX
-
Guidance Raised to ~$1 Billion
Full-year 2026 total global revenue guidance was lifted to approximately $1 billion from approximately $950 million, while BRIUMVI U.S. net product revenue guidance rose to approximately $915-$920 million from $890-$905 million.
-
Q3 Revenue Up 52%
Total global revenue reached $259.9 million, including BRIUMVI U.S. net product revenue of $232.6 million, up about 52% from the prior-year quarter.
-
Profitable Quarter, $556.7M Cash
Net income came in at $55.5 million ($0.35 diluted EPS), and cash, cash equivalents and investment securities stood at $556.7 million as of September 30, 2026.
-
$100M Buyback in Q3
The company repurchased approximately $100 million of common stock in Q3 2026 (~2.0 million shares at an average $49.43); to date, $300 million has been repurchased across programs (8.9 million shares, ~6% of shares outstanding, average $33.88).
Analysis · TGTX · Life Sciences
TG Therapeutics beat its own trajectory and raised full-year 2026 total revenue guidance to roughly $1 billion from about $950 million, with BRIUMVI U.S. net product revenue now targeted at $915-$920 million. Third-quarter revenue of $259.9 million and net income of $55.5 million show the commercial franchise is now solidly profitable. The company also bought back about $100 million of stock in the quarter at an average $49.43 — real cash returned while the shares trade near their 52-week high. The next hard data point is Phase 3 subcutaneous BRIUMVI topline, expected around year-end 2026 or early 2027, which will determine whether the franchise extends beyond IV dosing.
How filings like this one have moved
In the 30 days to Nov 9, 2026, 47.1% of the 1533 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.29%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, TGTX was trading at $63.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $9.2B. The 52-week trading range was $26.76 to $63.60. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.